http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008031878-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72be095f9a0887d8c66d81877f666fd6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aae6dbe01f19b543a4d00b66763cfc65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78e33ec15887bf7c1b545208c3031557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fcd4680edb04622cab1c611c664dc42 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55577 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-292 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
| filingDate | 2007-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_499017cd61a151b2c39f1066fea9a9fc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c6e2cc89fe0b3095cb940e270f29329 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bcab0d6ebb985fee8c08b1ce05b3cab |
| publicationDate | 2008-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2008031878-A1 |
| titleOfInvention | A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases |
| abstract | The present invention relates to a composition, comprising: i) an HBcAg1-x, wherein x is a whole number from the range from 100 to 160, a fragment of this antigen, a variant of this antigen or of the fragment of this antigen or at least two thereof, ii) an adjuvant comprising a saponin, and optionally iii) an HBsAg, a fragment from this antigen, a variant of this antigen or of the fragment of this antigen or at least two thereof, wherein the adjuvant comprises as saponin 50 to 90 wt.% of the fraction A obtained by the herein-described test method from Quillaja Saponaria Molina extract and 10 to 50 wt.% of the fraction C obtained by the herein-described test method from Quillaja Saponaria Molina extract, whereby the total amount of saponins of the fraction A and saponins of the fraction C is 100 wt.%; the adjuvant comprises, besides the saponin, cholesterol, phosphatidylcholine and decanoyl-N-methylglucamide. The invention also relates to a process for production of a composition, the composition obtainable by this process, a pharmaceutical formulation, the use of the composition or of the pharmaceutical formulation for treatment and/or prevention of HBV infections and HBV-mediated diseases, the use of the composition or of the pharmaceutical formulation for production of a pharmaceutical for treatment and/or for prevention of HBV-infections and HBV-mediated diseases as well as a process for treatment and/or for prevention of HBV-infections and HBV-mediated diseases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101942013-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101942013-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IL-275252-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019115817-A3 |
| priorityDate | 2006-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 129.